PPARGC1A and Pelizeaus-Merzbacher spectrum disorder: In the last decade, the PGC-1α signaling cascade has become an attractive therapeutic target to manipulate mitochondrial function, and several drugs acting on the PGC-1α pathway have been tested in preclinical models of PMD [74,81].